The Sage Group advised Zhimeng Biopharma on a worldwide license to GSK of CB06-036, a TLR8 Agonist
![](https://static.wixstatic.com/media/a60c5c_dc52190cfcf44a7cbac5774bc1776d7d~mv2.jpg/v1/fill/w_147,h_147,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/a60c5c_dc52190cfcf44a7cbac5774bc1776d7d~mv2.jpg)
In December 2022, GSK entered into an exclusive license agreement with biopharma company Zhimeng for CB06-036, a TLR8 agonist. Subject to successful completion of phase I, the agreement will allow GSK to develop, manufacture and commercialise CB06-036. If successful, CB06-036 could be used in combination, or as a sequential treatment with bepirovirsen, to potentially achieve functional cure in more patients.
The Sage Group advised Zhimeng Biopharma on this transaction.